US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5766629A
(en)
|
1995-08-25 |
1998-06-16 |
Sangstat Medical Corporation |
Oral cyclosporin formulations
|
US5985312A
(en)
*
|
1996-01-26 |
1999-11-16 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6368586B1
(en)
|
1996-01-26 |
2002-04-09 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6120806A
(en)
*
|
1997-06-25 |
2000-09-19 |
Whitmire; David R. |
Oral formulations for controlled release of alcohol deterrents
|
FR2775435B1
(fr)
*
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US20040259895A1
(en)
*
|
1998-05-28 |
2004-12-23 |
Medical Research Institute |
Oral formulation of lipid soluble thiamine and lipoic acid
|
US6905707B2
(en)
*
|
1998-05-28 |
2005-06-14 |
Medical Research Institute |
Controlled release arginine alpha ketoglutarate
|
US6197340B1
(en)
*
|
1998-05-28 |
2001-03-06 |
Medical Research Institute |
Controlled release lipoic acid
|
US20050085498A1
(en)
*
|
1998-05-28 |
2005-04-21 |
Byrd Edward A. |
Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
EP1117384A1
(de)
*
|
1998-10-01 |
2001-07-25 |
Elan Pharma International Limited |
Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US6984404B1
(en)
|
1998-11-18 |
2006-01-10 |
University Of Florida Research Foundation, Inc. |
Methods for preparing coated drug particles and pharmaceutical formulations thereof
|
ATE338120T2
(de)
|
1998-11-27 |
2006-09-15 |
Ucb Sa |
Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
DE69936534T2
(de)
|
1998-11-30 |
2008-03-13 |
Nanosphere, Inc., Northbrook |
Nanopartikel mit polymerschalen
|
US20020054914A1
(en)
*
|
1999-02-03 |
2002-05-09 |
Tulin Morcol |
Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
|
US20040258763A1
(en)
*
|
1999-02-03 |
2004-12-23 |
Bell Steve J.D. |
Methods of manufacture and use of calcium phosphate particles containing allergens
|
PT1150918E
(pt)
|
1999-02-03 |
2005-01-31 |
Biosante Pharmaceuticals Inc |
Metodo de fabrico de particulas terapeuticas de fosfato de calcio
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
EP1591437B1
(de)
|
1999-05-14 |
2009-11-25 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 und Tumornekrosefaktor-alpha Modulatoren,Synthese dieser Modulatoren und Methoden zur Anwendung dieser Modulatoren
|
EP1754488A1
(de)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
|
US6406745B1
(en)
*
|
1999-06-07 |
2002-06-18 |
Nanosphere, Inc. |
Methods for coating particles and particles produced thereby
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
RU2155602C1
(ru)
|
1999-11-30 |
2000-09-10 |
Оао "Куантум Сатис" |
Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
US20040171107A1
(en)
*
|
2000-02-23 |
2004-09-02 |
David Nelson |
Modified flourescent proteins
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
JP2003530156A
(ja)
*
|
2000-04-06 |
2003-10-14 |
ユニバーシティ ライセンス ホールディングス インコーポレイテッド |
創傷治癒を促進するための組成物および方法
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
CA2309575A1
(en)
*
|
2000-05-26 |
2001-11-26 |
James E. Guillet |
Internally cross-linked macromolecules
|
ES2374620T3
(es)
|
2000-06-20 |
2012-02-20 |
Corixa Corporation |
Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos.
|
EP1961819A3
(de)
|
2000-06-28 |
2008-11-12 |
Corixa Corporation |
Zusammensetzungen und Verfahren zur Heilung und Diagnose von Lungenkrebs
|
US6602523B1
(en)
*
|
2000-08-17 |
2003-08-05 |
Technology Holding, Llc. |
Composite material and process for increasing bioavailability and activity of a beneficial agent
|
JP4395549B2
(ja)
*
|
2000-11-16 |
2010-01-13 |
ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア |
薬物及び発酵生成物の発見のための海洋放線菌分類群
|
WO2002045737A2
(en)
*
|
2000-12-07 |
2002-06-13 |
Board Of Regents, The University Of Texas System |
Methods of treatment involving human mda-7
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US6869617B2
(en)
*
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
EP1515982A4
(de)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
|
US20030185892A1
(en)
*
|
2001-08-17 |
2003-10-02 |
Bell Steve J. D. |
Intraocular delivery compositions and methods
|
DK1429731T3
(da)
*
|
2001-09-19 |
2007-05-14 |
Elan Pharma Int Ltd |
Nanopartikelformuleringer indeholdende insulin
|
BR0212833A
(pt)
*
|
2001-09-26 |
2004-10-13 |
Baxter Int |
Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
ES2405405T3
(es)
|
2001-12-17 |
2013-05-31 |
Corixa Corporation |
Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
JP2005533000A
(ja)
*
|
2002-03-05 |
2005-11-04 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
Mda−7に関与する免疫誘導を増強する方法
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
US7332469B2
(en)
|
2002-04-05 |
2008-02-19 |
Board Of Regents The University Of Texas System |
Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
KR101170653B1
(ko)
|
2002-08-12 |
2012-08-03 |
제네렉스, 인코포레이티드 |
폭스바이러스 및 암과 관련된 방법 및 조성물
|
WO2004034970A2
(en)
*
|
2002-09-27 |
2004-04-29 |
Nereus Pharmaceuticals, Inc. |
Macrocyclic lactams
|
US20050051968A1
(en)
*
|
2002-11-13 |
2005-03-10 |
Froesel David William |
Washer toss game
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
US7531191B2
(en)
*
|
2002-12-17 |
2009-05-12 |
Massachusetts Institute Of Technology |
Stimuli-responsive systems for controlled drug delivery
|
EP1589934B1
(de)
|
2003-01-06 |
2015-09-23 |
Corixa Corporation |
Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP1596872B1
(de)
*
|
2003-01-24 |
2011-06-22 |
Flora Technology Inc. |
Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
|
WO2004078124A2
(en)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving mda-7
|
US7381409B2
(en)
*
|
2003-06-16 |
2008-06-03 |
Celltech R&D, Inc. |
Antibodies specific for sclerostin and methods of screening and use therefor
|
MXPA05013982A
(es)
*
|
2003-06-20 |
2006-05-25 |
Nereus Pharmaceuticals Inc |
Metodos para utilizar compuestos {3.2.0} heterociclicos y sus analogos.
|
NZ544858A
(en)
*
|
2003-06-20 |
2009-07-31 |
Univ California |
Salinosporamides and methods for use thereof
|
CN101291653B
(zh)
|
2003-07-16 |
2012-06-27 |
普洛体维生物治疗公司 |
脂质包封的干扰rna
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
EP1525890A1
(de)
*
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophor Komplex
|
WO2005041656A2
(en)
|
2003-10-22 |
2005-05-12 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in tissues and organs
|
WO2005082396A2
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
ATE509018T1
(de)
*
|
2004-01-23 |
2011-05-15 |
Nereus Pharmaceuticals Inc |
Als antimikrobielle mittel geeignete bisindolpyrrole
|
DE602005021756D1
(de)
*
|
2004-02-13 |
2010-07-22 |
Nod Pharmaceuticals Inc |
Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
JP2007535559A
(ja)
|
2004-04-30 |
2007-12-06 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
[3.2.0]複素環式化合物及びその使用法
|
AU2005285513B2
(en)
|
2004-05-25 |
2011-02-24 |
Oregon Health And Science University |
SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
|
WO2006004774A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Stanford University |
Laulimalide analogues as therapeutic agents
|
FR2872703B1
(fr)
*
|
2004-07-07 |
2006-10-06 |
Ethypharm Sa |
Nanoparticules polymeriques composites
|
CN1732962A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
阿霉素-聚氰基丙烯酸正丁脂纳米粒的制备方法
|
CN1733313A
(zh)
*
|
2004-08-11 |
2006-02-15 |
张阳德 |
聚氰基丙烯酸正丁酯纳米颗粒的制备方法
|
US20060078623A1
(en)
*
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
AU2005287090A1
(en)
|
2004-09-18 |
2006-03-30 |
Department Of Veterans Affairs |
Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
|
CN101043891A
(zh)
|
2004-09-18 |
2007-09-26 |
巴尔的摩马里兰大学 |
靶向NCCa-ATP通道的治疗剂及其使用方法
|
US7282194B2
(en)
*
|
2004-10-05 |
2007-10-16 |
Gp Medical, Inc. |
Nanoparticles for protein drug delivery
|
US20090041812A1
(en)
*
|
2004-11-01 |
2009-02-12 |
Bell Steve J D |
Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
|
AU2005311709B2
(en)
|
2004-12-03 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating neoplastic diseases
|
EP1885746B1
(de)
|
2005-02-08 |
2012-01-11 |
Research Development Foundation |
Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
|
US20070009484A1
(en)
*
|
2005-02-08 |
2007-01-11 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving MDA-7 for the treatment of cancer
|
ES2259914B1
(es)
*
|
2005-03-14 |
2007-06-16 |
Advanced In Vitro Cell Technologies, S.L. |
Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
|
WO2006104890A2
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
WO2007012979A2
(en)
|
2005-04-22 |
2007-02-01 |
Universite De Geneve |
Polylactide compositions and uses thereof
|
ES2524570T3
(es)
|
2005-04-29 |
2014-12-10 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de prevención o tratamiento de infección por M. tuberculosis
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
AU2006259594A1
(en)
*
|
2005-06-14 |
2006-12-28 |
Baxter Healthcare S.A. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
EP2311795A3
(de)
|
2005-07-21 |
2011-12-28 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1- und Tumornekrosefaktor-Alpha-Modulatoren, Synthese solcher Modulatoren und Verfahren unter Anwendung solcher Modulatoren
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
JPWO2007024026A1
(ja)
*
|
2005-08-25 |
2009-03-05 |
明石 満 |
T細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
|
CA2621982C
(en)
*
|
2005-09-07 |
2017-11-28 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
EP1954245A2
(de)
*
|
2005-11-15 |
2008-08-13 |
Baxter International Inc. |
Zusammensetzungen aus lipoxygenase-hemmern
|
WO2007062399A2
(en)
|
2005-11-23 |
2007-05-31 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
EP2455362A1
(de)
|
2005-11-28 |
2012-05-23 |
GTX, Inc. |
Nuklearrezeptor-bindende Wirkstoffe
|
EP1979488A4
(de)
|
2006-01-09 |
2009-05-27 |
Univ California |
Immunstimulierende kombinationen aus tnfrsf, tlr, nlr, rhr, purinergischem rezeptor, und zytokin-rezeptor-antaonisten für impfstoffe und die tumorimmuntherapie
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
EP1876188A1
(de)
*
|
2006-07-04 |
2008-01-09 |
NanoDel Technologies GmbH |
Zweistufiges Polymerisationsverfahren in Miniemulsion
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8080645B2
(en)
*
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
US8481023B2
(en)
|
2006-09-15 |
2013-07-09 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
CA2663962A1
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US8466154B2
(en)
|
2006-10-27 |
2013-06-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to wrapping of dehydrons
|
WO2008133722A2
(en)
*
|
2006-11-10 |
2008-11-06 |
Ucb Pharma S.A. |
Anti human sclerostin antibodies
|
EP2097450A2
(de)
|
2006-11-10 |
2009-09-09 |
Amgen Inc. |
Diagnostika und therapeutika auf antikörperbasis
|
EP2567975A3
(de)
|
2006-11-21 |
2013-07-03 |
The Regents of The University of California |
Modulation von RHAMM (CD168) zur selektiven Fettgewebeentwicklung
|
US20080138418A1
(en)
*
|
2006-12-07 |
2008-06-12 |
Tong Shen Enterprise Co., Ltd. |
Nanoparticles composed of alkyl-cyanoacrylate polymers
|
WO2008089103A2
(en)
|
2007-01-12 |
2008-07-24 |
University Of Maryland, Baltimore |
Targeting ncca-atp channel for organ protection following ischemic episode
|
US8679539B2
(en)
*
|
2007-01-31 |
2014-03-25 |
Tong Shen Enterprise Co., Ltd. |
Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
|
US7824698B2
(en)
*
|
2007-02-02 |
2010-11-02 |
Nereus Pharmaceuticals, Inc. |
Lyophilized formulations of Salinosporamide A
|
CA2677264C
(en)
|
2007-02-02 |
2021-11-30 |
Baylor College Of Medicine |
Compositions and methods for the treatment of metabolic disorders
|
WO2008098160A1
(en)
|
2007-02-09 |
2008-08-14 |
University Of Maryland, Baltimore |
Antagonists of a non-selective cation channel in neural cells
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
CN101687027B
(zh)
*
|
2007-04-04 |
2015-01-28 |
传染性疾病研究院 |
包含结核分枝杆菌多肽及其融合的免疫原性组合物
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
EP2191001B1
(de)
|
2007-04-09 |
2016-06-08 |
University of Florida Research Foundation, Inc. |
Raav-vektorzusammensetzungen mit tyrosin-modifizierten capsidproteinen und verwendungsverfahren
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
AU2008259342B2
(en)
|
2007-06-04 |
2014-07-10 |
Ben-Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
US8557867B2
(en)
|
2007-06-22 |
2013-10-15 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Inhibitors of NCCa-ATP channels for therapy
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US8821885B2
(en)
|
2007-08-27 |
2014-09-02 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
AU2008343745B2
(en)
|
2007-10-01 |
2012-05-10 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system and methods of use
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
KR20100101656A
(ko)
*
|
2007-12-14 |
2010-09-17 |
암젠 인크 |
항-스클레로스틴 항체를 사용한 골절 치료 방법
|
ES2535419T3
(es)
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
CN101959523A
(zh)
|
2007-12-27 |
2011-01-26 |
公立大学法人横浜市立大学 |
革兰氏阳性细菌用抗菌剂
|
JP5475753B2
(ja)
|
2008-04-15 |
2014-04-16 |
プロチバ バイオセラピューティクス インコーポレイティッド |
核酸送達用の脂質製剤
|
CA2721380A1
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
US8669225B2
(en)
*
|
2008-05-09 |
2014-03-11 |
South Dakota State University |
Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
|
JP2011519975A
(ja)
*
|
2008-05-12 |
2011-07-14 |
ネレアス ファーマシューティカルズ インコーポレイテッド |
プロテアソーム阻害剤としてのサリノスポラミド誘導体
|
US8404471B2
(en)
|
2008-06-26 |
2013-03-26 |
Atyr Pharma, Inc. |
Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
|
WO2010033560A2
(en)
|
2008-09-16 |
2010-03-25 |
University Of Maryland, Baltimore |
Sur1 inhibitors for therapy
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
ES2552773T3
(es)
|
2009-02-27 |
2015-12-02 |
Atyr Pharma, Inc. |
Motivos estructurales de polipéptidos asociados con la actividad de señalización celular
|
EP3255146B1
(de)
|
2009-03-16 |
2019-05-15 |
Pangu Biopharma Limited |
Zusammensetzungen und verfahren mit histidyl-trna-synthetase-spleissvarianten mit nicht-kanonischen biologischen aktivitäten
|
US20100310576A1
(en)
|
2009-03-31 |
2010-12-09 |
Adams Ryan A |
COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES
|
US20120294868A1
(en)
|
2009-04-24 |
2012-11-22 |
Edwards James R |
Anti-tgf-beta induction of bone cell function and bone growth
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
EP2456304B1
(de)
|
2009-07-24 |
2015-08-19 |
Baylor College Of Medicine |
Verfahren zur modulierung von säuren mit verzweigten ketten und anwendungen davon
|
CA2771769C
(en)
|
2009-08-28 |
2019-10-29 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
KR101838472B1
(ko)
|
2009-09-14 |
2018-03-15 |
신라젠(주) |
종양 용해 백시니아 바이러스 병용 암 치료요법
|
CA2775092A1
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
MX365946B
(es)
|
2009-12-10 |
2019-06-19 |
Turnstone Lp |
Rabdovirus oncolitico.
|
JP5819314B2
(ja)
|
2009-12-11 |
2015-11-24 |
エータイアー ファーマ, インコーポレイテッド |
炎症を調節するためのアミノアシルtRNAシンテターゼ
|
US20110150885A1
(en)
|
2009-12-11 |
2011-06-23 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
JP2013514992A
(ja)
|
2009-12-18 |
2013-05-02 |
アムジェン インコーポレイテッド |
Wise結合剤およびエピトープ
|
PT2528621T
(pt)
|
2010-01-27 |
2016-12-20 |
Glaxosmithkline Biologicals Sa |
Antigénios de tuberculose modificados
|
KR20200047642A
(ko)
|
2010-04-23 |
2020-05-07 |
유니버시티 오브 플로리다 리서치 파운데이션, 인크. |
레베르 선천성 흑내장-1(lca1)의 치료를 위한 재조합 아데노-관련된 바이러스-구아닐레이트 사이클라제 조성물 및 방법
|
ES2689520T3
(es)
|
2010-04-23 |
2018-11-14 |
Kempharm, Inc. |
Formulación terapéutica para reducir los efectos secundarios de fármacos
|
EP3536781A1
(de)
|
2010-04-23 |
2019-09-11 |
University of Massachusetts |
Auf das zns abzielende vektoren und verfahren zur verwendung davon
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
JP6066900B2
(ja)
|
2010-04-26 |
2017-01-25 |
エータイアー ファーマ, インコーポレイテッド |
システイニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2797362C
(en)
|
2010-04-27 |
2020-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
JP6008837B2
(ja)
|
2010-04-28 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
アラニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
WO2011139854A2
(en)
|
2010-04-29 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
CA2797393C
(en)
|
2010-04-29 |
2020-03-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
|
WO2011150279A2
(en)
|
2010-05-27 |
2011-12-01 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
JP6008841B2
(ja)
|
2010-05-03 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
メチオニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
CA2797277C
(en)
|
2010-05-03 |
2021-02-23 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
EP2566495B1
(de)
|
2010-05-03 |
2017-03-01 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen
|
EP2566499B1
(de)
|
2010-05-04 |
2017-01-25 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
PT2569010T
(pt)
|
2010-05-14 |
2017-05-31 |
Amgen Inc |
Formulações de anticorpos de concentração elevada
|
CN103200953B
(zh)
|
2010-05-14 |
2017-02-15 |
Atyr 医药公司 |
与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
JP6027965B2
(ja)
|
2010-05-17 |
2016-11-16 |
エータイアー ファーマ, インコーポレイテッド |
ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
WO2011153277A2
(en)
|
2010-06-01 |
2011-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
US10865445B2
(en)
|
2010-08-18 |
2020-12-15 |
Fred Hutchinson Cancer Research Center |
Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL
|
EP2608801B1
(de)
|
2010-08-25 |
2019-08-21 |
aTyr Pharma, Inc. |
Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von tyrosyl-trna-synthetasen
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
BR112013011420A2
(pt)
|
2010-11-08 |
2016-08-02 |
Infectious Disease Res Inst |
vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
|
JP6121910B2
(ja)
|
2011-01-04 |
2017-04-26 |
シラジェン バイオセラピューティクス インコーポレイテッド |
腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
|
WO2012097093A2
(en)
|
2011-01-11 |
2012-07-19 |
Fate Therapeutics, Inc. |
Novel wnt compositions and therapeutic uses of such compositions
|
WO2012103328A1
(en)
|
2011-01-26 |
2012-08-02 |
The Methodist Hospital Research Institute |
Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use
|
EP2670849A1
(de)
|
2011-02-03 |
2013-12-11 |
Mirna Therapeutics, Inc. |
Synthetische mimetika von mir-124
|
MY165507A
(en)
|
2011-02-03 |
2018-03-28 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
US8986739B2
(en)
|
2011-02-28 |
2015-03-24 |
Nicholas V. Perricone |
Treatment of urinary incontinence using nitrone spin traps
|
EP2681242B1
(de)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin- und dkk-1-bispezifische bindemittel
|
EA029956B1
(ru)
|
2011-03-25 |
2018-06-29 |
Эмджен Инк. |
Кристаллы антител против склеростина и составы на их основе
|
JP5938836B2
(ja)
|
2011-03-31 |
2016-06-22 |
株式会社ナノカム |
高次構造体が示す抗細胞効果の新規調整技法
|
US20140127192A1
(en)
|
2011-04-19 |
2014-05-08 |
Amgen Inc |
Method for treating osteoporosis
|
US9364532B2
(en)
|
2011-06-08 |
2016-06-14 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions and methods for glioblastoma treatment
|
US8858928B2
(en)
|
2011-06-10 |
2014-10-14 |
Bluebird Bio, Inc. |
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
PL2734634T3
(pl)
|
2011-07-22 |
2020-03-31 |
The University Of Chicago |
Igf-1 do zastosowania do leczenia migreny
|
DK2739311T3
(en)
|
2011-08-04 |
2018-04-23 |
Amgen Inc |
Method of treating bone slit defects
|
US9655905B2
(en)
|
2011-09-14 |
2017-05-23 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
US9644005B2
(en)
|
2011-09-21 |
2017-05-09 |
King Abdullah University Of Science And Technology |
Didemnin biosynthetic gene cluster in Tistrella mobilis
|
KR101931403B1
(ko)
|
2011-09-23 |
2018-12-21 |
블루버드 바이오, 인코포레이티드. |
개선된 유전자 치료 방법
|
WO2013095736A2
(en)
|
2011-09-27 |
2013-06-27 |
The Methodist Hospital Research Institute |
Gold-in-silicon nanoassembly for thermal therapy and methods of use
|
DK3269802T3
(da)
|
2011-09-30 |
2020-02-03 |
Bluebird Bio Inc |
Forbindelser til forbedret virustransduktion
|
WO2013059676A1
(en)
|
2011-10-21 |
2013-04-25 |
Subhash Desai |
Compositions for reduction of side effects
|
CN104136026B
(zh)
|
2011-10-31 |
2018-03-02 |
卫理公会医院研究所 |
包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
|
MX359234B
(es)
|
2011-11-11 |
2018-09-20 |
Hutchinson Fred Cancer Res |
Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer.
|
CA3131037A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013086433A1
(en)
|
2011-12-07 |
2013-06-13 |
The Methodist Hospital Research Institute |
Sirna compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
CN107126560A
(zh)
|
2011-12-28 |
2017-09-05 |
安进公司 |
通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法
|
WO2013108871A1
(ja)
|
2012-01-19 |
2013-07-25 |
Shirotake Shoichi |
植物病原細菌用抗菌剤
|
CA3207612A1
(en)
|
2012-01-26 |
2013-08-01 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
US20150024037A1
(en)
|
2012-02-16 |
2015-01-22 |
The University Of Toledo |
Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
|
US9352042B2
(en)
|
2012-02-24 |
2016-05-31 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
AR092821A1
(es)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
Conjugado de derivado de acido graso-polimero
|
EP2849775A1
(de)
*
|
2012-05-16 |
2015-03-25 |
Glaxo Group Limited |
Mit polypeptid beladene poca-nanopartikel zur oralen verabreichung
|
CA2871477A1
(en)
|
2012-05-23 |
2013-11-28 |
The Ohio State University |
Lipid nanoparticle compositions for antisense oligonucleotides delivery
|
WO2014006100A1
(en)
|
2012-07-05 |
2014-01-09 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
BR112015002483A2
(pt)
|
2012-08-03 |
2017-11-07 |
Infectious Disease Res Inst |
composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
|
EP2931300A1
(de)
*
|
2012-08-14 |
2015-10-21 |
Wockhardt Limited |
Mikropartikuläre pharmazeutische zusammensetzungen aus polypeptiden
|
WO2014027253A1
(en)
*
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CA2899889A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an anti-activin-a compound to a subject
|
RU2684211C2
(ru)
|
2013-02-21 |
2019-04-04 |
Тёрнстоун Лимитед Партнершип |
Композиция вакцины
|
WO2014160339A1
(en)
|
2013-03-13 |
2014-10-02 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
WO2014186746A1
(en)
|
2013-05-16 |
2014-11-20 |
University Of Florida Research Foundation, Inc. |
HAIRPIN mRNA ELEMENTS AND METHODS FOR THE REGULATION OF PROTEIN TRANSLATION
|
US20160151284A1
(en)
|
2013-07-23 |
2016-06-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
CN106061940A
(zh)
|
2013-11-05 |
2016-10-26 |
本古里安大学内盖夫研究发展局 |
治疗糖尿病和由其引发的并发疾病的化合物
|
NZ720311A
(en)
|
2013-12-02 |
2022-10-28 |
Baylor College Medicine |
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
|
US10351644B2
(en)
|
2014-02-27 |
2019-07-16 |
Shoichi Shirotake |
Antiviral drug
|
CN111620830A
(zh)
|
2014-03-14 |
2020-09-04 |
北卡罗来纳大学教堂山分校 |
用于抑制雄性生育力的小分子
|
SG11201607795UA
(en)
|
2014-04-08 |
2016-10-28 |
Methodist Hospital |
Inos-inhibitory compositions and their use as breast cancer therapeutics
|
US9693994B2
(en)
|
2014-04-09 |
2017-07-04 |
Research Development Foundation |
Class IIa HDAC inhibitors for the treatment of infection
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
JP6768527B2
(ja)
|
2014-06-20 |
2020-10-14 |
アベオ ファーマシューティカルズ, インコーポレイテッド |
Gdf15調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
|
WO2015196142A1
(en)
|
2014-06-20 |
2015-12-23 |
Aveo Pharmaceuticals, Inc. |
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
EP3188600B1
(de)
|
2014-09-01 |
2022-05-11 |
Academia Sinica |
Tierlebensdauermodell und zugehörige verfahren zur verlängerung der lebensdauer und zur hemmung von tumorigenese
|
WO2016036674A1
(en)
|
2014-09-02 |
2016-03-10 |
Bhupinder Singh |
Deuterated or a non-deuterated molecule and pharmaceutical formulations
|
WO2016037138A1
(en)
|
2014-09-04 |
2016-03-10 |
Memorial Sloan-Kettering Cancer Center |
Global gene therapy for treating hemoglobinopathies
|
US20170306008A1
(en)
|
2014-09-25 |
2017-10-26 |
Aveo Pharmaceuticals, Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
US10415037B2
(en)
|
2014-10-02 |
2019-09-17 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis B virus gene expression
|
EP3795580A1
(de)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
Hocheffiziente bibliotheksidentifizierte aav-vektoren
|
US10751317B2
(en)
|
2014-10-08 |
2020-08-25 |
Pacific Northwest Research Institute |
Methods and compositions for increasing the potency of antifungal agents
|
CA2964272A1
(en)
|
2014-10-21 |
2016-04-28 |
Guangping Gao |
Recombinant aav variants and uses thereof
|
WO2016073184A1
(en)
|
2014-11-04 |
2016-05-12 |
Dana Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
WO2016145217A1
(en)
|
2015-03-10 |
2016-09-15 |
The Trustees Of Columbia University In The City Of New York |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
WO2016172026A1
(en)
|
2015-04-20 |
2016-10-27 |
The Board Of Regents Of The University Of Texas System |
Clec11a is a bone growth agent
|
CA3019315A1
(en)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation of aav vector transgene expression
|
US9976136B2
(en)
|
2015-05-14 |
2018-05-22 |
Longhorn Vaccines And Diagnostics, Llc |
Rapid methods for the extraction of nucleic acids from biological samples
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
WO2016205615A1
(en)
|
2015-06-17 |
2016-12-22 |
The Johns Hopkins University |
Tdp-43 in degenerative disease
|
CN108350455A
(zh)
|
2015-07-29 |
2018-07-31 |
阿布特斯生物制药公司 |
用于使b型肝炎病毒基因表达沉默的组合物和方法
|
US20170056485A1
(en)
|
2015-08-31 |
2017-03-02 |
Sciotec Diagnostic Technologies Gmbh |
Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
EP3408382B1
(de)
|
2016-01-27 |
2022-03-23 |
Oncorus, Inc. |
Oncolytische virale vektoren und verwendungen davon
|
US10695322B2
(en)
|
2016-01-29 |
2020-06-30 |
The Johns Hopkins University |
Inhibitors of bacterial growth
|
EP3413928B1
(de)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
|
US11040025B2
(en)
|
2016-02-17 |
2021-06-22 |
The Johns Hopkins University |
Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
|
US11149060B2
(en)
|
2016-02-19 |
2021-10-19 |
University Of Delaware |
Functionalized nanoparticles for enhanced affinity precipitation of proteins
|
WO2017147215A1
(en)
|
2016-02-22 |
2017-08-31 |
The Methodist Hospital |
Biomimetic proteolipid vesicle compositions and uses thereof
|
US11180758B2
(en)
|
2016-02-24 |
2021-11-23 |
The Johns Hopkins University |
Antiviral proteins and their uses in therapeutic methods
|
MX2018010586A
(es)
|
2016-03-02 |
2019-03-28 |
Univ Texas |
Nanovacuna de activacion de "sting" para inmunoterapia.
|
CN109195636B
(zh)
|
2016-03-03 |
2022-07-05 |
马萨诸塞大学 |
用于非病毒基因转移的末端封闭型线性双链体dna
|
WO2017155935A1
(en)
|
2016-03-07 |
2017-09-14 |
The Johns Hopkins University |
Pharmaceutical agents targeting cancer stem cells
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
EP3426785A4
(de)
|
2016-03-10 |
2019-12-25 |
The Johns Hopkins University |
Verfahren zur herstellung von aggregatfreien monomeren diphtherietoxinfusionsproteinen und therapeutische verwendungen
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
CN109414417A
(zh)
|
2016-03-17 |
2019-03-01 |
约翰·霍普金斯大学 |
通过paris的法尼基化预防或治疗帕金森症的方法
|
EP3436609B1
(de)
|
2016-03-30 |
2022-05-04 |
The Johns Hopkins University |
Olfr90-spezifität und nachweisverfahren
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
CA3024313A1
(en)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
WO2018006052A1
(en)
|
2016-06-30 |
2018-01-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
WO2018009553A1
(en)
|
2016-07-05 |
2018-01-11 |
University Of Massachusetts |
Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
|
EP3488005A4
(de)
|
2016-07-19 |
2020-07-29 |
University of Pittsburgh- Of the Commonwealth System of Higher Education |
Auf stat3 abzielende onkolytische viren
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
US11491114B2
(en)
|
2016-10-12 |
2022-11-08 |
Curioralrx, Llc |
Formulations for enteric delivery of therapeutic agents
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
DK4008344T3
(da)
|
2017-01-27 |
2024-01-29 |
Methodist Hospital |
Kerne/skal struktur platform til immunterapi
|
EP3579824A1
(de)
|
2017-02-12 |
2019-12-18 |
Ben-Gurion University Of The Negev Research And Development Authority |
Telomerase-aktivierende verbindungen zur verwendung in der fertilität und verwandte anwendungen
|
CA3062450A1
(en)
|
2017-05-03 |
2018-11-08 |
Biomarin Pharmaceutical Inc. |
Improved lentiviruses for transduction of hematopoietic stem cells
|
AU2018281145A1
(en)
|
2017-06-06 |
2020-01-02 |
University Of Massachusetts |
Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
CN111212656A
(zh)
|
2017-07-26 |
2020-05-29 |
昂克诺斯公司 |
溶瘤病毒载体及其用途
|
WO2019028469A1
(en)
|
2017-08-04 |
2019-02-07 |
The Methodist Hospital |
FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
|
JP7339942B2
(ja)
|
2017-09-08 |
2023-09-06 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サポニンを含むリポソーム製剤および使用方法
|
US20200330541A1
(en)
|
2017-11-16 |
2020-10-22 |
University Of Maine System Board Of Trustees |
Compositions and methods for modulating endothelial cell migration and angiogenesis
|
EP3720509A4
(de)
|
2017-12-06 |
2021-12-08 |
Memorial Sloan-Kettering Cancer Center |
Globingentherapie zur behandlung von hämoglobinopathien
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
US11246857B2
(en)
|
2017-12-14 |
2022-02-15 |
The Johns Hopkins University |
Anti-fungal inhibitors
|
MX2020007011A
(es)
|
2018-01-05 |
2020-12-03 |
Ottawa Hospital Res Inst |
Vectores de vaccinia modificados.
|
WO2020036635A2
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
KR20200135433A
(ko)
|
2018-03-23 |
2020-12-02 |
유니버시티 오브 매사추세츠 |
골 장애 치료를 위한 유전자 치료제
|
EP3773612A4
(de)
|
2018-03-28 |
2022-01-12 |
Herbalife International of America, Inc. |
Acetylierung von polysacchariden
|
MX2020010092A
(es)
|
2018-03-30 |
2020-10-28 |
Amgen Inc |
Variantes de anticuerpo c-terminales.
|
EP3784290A4
(de)
|
2018-04-27 |
2022-03-23 |
University of Massachusetts |
Durch in-vivo-bibliotheksauswahl identifizierte aav-kapside
|
US20210207168A1
(en)
|
2018-05-08 |
2021-07-08 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
KR102167755B1
(ko)
|
2018-05-23 |
2020-10-19 |
주식회사 큐어바이오 |
단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
|
US20230048010A1
(en)
|
2018-09-28 |
2023-02-16 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
CN113164625A
(zh)
|
2018-09-28 |
2021-07-23 |
哈佛大学的校长及成员们 |
用于基因表达的突变体反向四环素反式激活因子
|
EP3887522A1
(de)
|
2018-11-29 |
2021-10-06 |
University of Massachusetts |
Modulation von sptlc1 über rekombinante adeno-assoziierte vektoren
|
EP3908312A2
(de)
|
2019-01-12 |
2021-11-17 |
The Methodist Hospital |
Selbstorganisiertes peptidnanoteilchen und seine verwendung
|
WO2020163766A1
(en)
|
2019-02-07 |
2020-08-13 |
Baylor College Of Medicine |
Periosteal skeletal stem cells in bone repair
|
US20220054655A1
(en)
|
2019-02-22 |
2022-02-24 |
University Of Massachusetts |
Oxr1 gene therapy
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
WO2021050970A1
(en)
|
2019-09-13 |
2021-03-18 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
KR20220078650A
(ko)
|
2019-10-10 |
2022-06-10 |
온코루스, 인크. |
이중 바이러스 및 이중 종양용해 바이러스 및 치료 방법
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
KR20220144377A
(ko)
|
2020-01-30 |
2022-10-26 |
우모자 바이오파마 인코포레이티드 |
이중특이적 형질도입 촉진제
|
KR20230113689A
(ko)
|
2020-03-31 |
2023-08-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 변이체 및 그의 용도
|
CA3188708A1
(en)
|
2020-08-07 |
2022-02-10 |
Access To Advanced Health Institute |
Purified saponins and chromatographic process for purification of same
|
EP4255457A1
(de)
|
2020-12-03 |
2023-10-11 |
University of Massachusetts |
Entwicklung von neuen gentherapeutika für fibrodysplasia ossificans progressiva
|
KR20220082558A
(ko)
|
2020-12-10 |
2022-06-17 |
재단법인 의약바이오컨버젼스연구단 |
면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
|
KR20230143150A
(ko)
|
2021-01-27 |
2023-10-11 |
우모자 바이오파마 인코포레이티드 |
항-cd19 키메라 항원 수용체를 발현하는 세포를 생성하기 위한 렌티바이러스
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
WO2023144393A1
(en)
|
2022-01-28 |
2023-08-03 |
Fundació Centre De Regulació Genòmica |
Therapeutic cytokines and methods
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2023215481A1
(en)
|
2022-05-05 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
INTERFERING RNA THERAPY FOR PLN-R14del CARDIOMYOPATHY
|
WO2023225569A1
(en)
|
2022-05-17 |
2023-11-23 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|